Search
Corifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalElonva is available only by prescription [L2270]. In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug. … This means that it is made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa [L2270].
Products: Elonva Solution for Injection 150mcg/0.5ml, Elonva Solution for Injection 100mcg/0.5mlEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria … [L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
Products: Soliris Concentrate for Solution for Infusion 300mg/vial, Soliris 10mg/ml Concentrate for Solution for InfusionSatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after … This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination.
Products: ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML, ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringeFerric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigational[L11581,L11587] Clinical trials show that it is non-inferior to [iron sucrose], another form of iron that is often administered in iron deficiency, and less likely to cause serious hypersensitivity that … The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.
Products: MONOFER® SOLUTION FOR INJECTION OR INFUSION 100 MG/ML, Monofer 100 mg/ml solution for injection/infusion in vialsAlglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalAglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
Products: Myozyme Powder for Solution for Injection, (Alglucosidase alfa) 50mg Powder for Solution for InfusionAlemtuzumab
go.drugbank.com/drugs/DB00087ApprovedInvestigationalAlemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. … [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).
Products: LEMTRADA Concentrate for Solution for Infusion 12 mg, LEMTRADA CONCENTRATE FOR SOLUTION FOR INFUSION 12 MG/ 1.2 MLIsavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalFollowing administration, isavuconazonium undergoes biotransformation to form the active moiety, isavuconazole, for the antifungal actions. … It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseProducts: CRESEMBA (POWDER FOR SOLUTION FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 MG/VIAL)Idarubicin
go.drugbank.com/drugs/DB01177ApprovedInvestigationalThe compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Products: ZAVEDOS FOR INJECTION 5 mg/vial, ZAVEDOS FOR INJECTION 10 mg/vialOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin … [A251590] It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease.
Products: XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalIt further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®
Categories: Drugs for Treatment of Bone DiseasesProducts: XGEVA 120mg Solution for Injection, XGEVA Solution for Injection 120 mg/vial